Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft

Zacks Equity Research

Baxter International Inc. BAX recently received the FDA approval of Altapore Shape Bioactive Bone Graft — the latest addition to the company’s next-generation bone graft substitute product line. The approval is likely to provide Baxter’s Advanced Surgery Advanced Surgery business line a substantial boost.

Notably, the entire Altapore product line has been developed to improve bone growth with optimized porosity that promotes vascularization, which plays a key role in the bone formation process by providing oxygen, nutrients and growth factors crucial for bone development.

Altapore Shape at a Glance

Altapore Shape is an implant developed to fill bony voids or gaps of the skeletal system, including in the pelvis, extremities and posterolateral spine that are surgically created or result from trauma. Altapore Shape can be utilized by itself, with autograft as a bone graft extender or with autogenous bone marrow aspirate.

Benefits of Altapore Shape

A recent clinical study demonstrates posterolateral fusion success related to improved patient outcomes, which includes reduced pain from baseline.

Altapore Share has been developed to boost bone growth and help achieve fusion that can lead to reduction in pain and other improved clinical outcomes for patients.


The introduction of this new format to the Altapore product line can enable surgeons with versatile tools to advance the art of healing and boost clinical outcomes during a surgery.

Recent Development

In May, Baxter received the CE marking and regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for the Evo IQ Syringe Infusion System. The system has been developed to optimize efficiency for clinicians, thereby enhancing flexibility to help meet future demands. This approval is likely to strengthen its Medication Delivery segment and global presence.

Market Prospects

Per a report by Medgadget, the global bone grafts and substitutes market was valued at $3.05 billion in 2019 and is anticipated to witness a robust CAGR of 5.5% over the forecast period (2019-2027).

Hence this development is a well-timed one for Baxter.

Price Performance

Over the past year, shares of this Zacks Rank #4 (Sell) stock company have gained 3.9% against the industry’s decline of 7.7%.

Stocks to Consider

Some better-ranked stocks from the broader medical space include Quest Diagnostics Inc. DGX, West Pharmaceutical Services, Inc. WST and Laboratory Corporation of America Holdings LH. While Quest Diagnostics and Laboratory Corporation sport a Zacks Rank #1 (Strong Buy), West Pharmaceutical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Quest Diagnostics has an estimated long-term earnings growth rate of 7.6%.

West Pharmaceutical has a projected long-term earnings growth rate of 9.2%.

Laboratory Corp. has an estimated long-term earnings growth rate of 6.1%.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report
Baxter International Inc. (BAX) : Free Stock Analysis Report
Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research